Although the transgenic cohort was limited, the complete lack of tumor formation in Csn6‐KO KPPC mice (as evidenced by 0/3 versus 3/3 in KPP controls) robustly supports a tumor‐suppressive role of CSN6 ablation, which is consistent with our in vitro and xenograft models and aligns with previous findings in other cancer types.[11, 13]. The gene discussed is COPS6; the disease is cancer.